Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14614093 | 0.83 | MAPK8 (0.42) | MAPK8MAPK10ALDH1A1GSK3BPRNP | |
| SCHEMBL2080157 | 0.82 | MAPK8 (0.41) | MAPK8MAPK10ALDH1A1GSK3BPRNP | |
| SCHEMBL2083788 | 0.82 | MAPK8 (0.41) | MAPK8MAPK10ALDH1A1GSK3BPRNP | |
| SCHEMBL12077076 | 0.82 | PTPN2 (0.43) | NPSR1KMT2AMEN1AXLLMNA | |
| SCHEMBL15895178 | 0.80 | GSK3B (0.43) | MAPK8MAPK10ALDH1A1GSK3BPRNP | |
| SCHEMBL158675 | 0.79 | KMT2A (0.54) | MAPK8MAPK10ALDH1A1PPARGNPSR1 | |
| SCHEMBL18070616 | 0.78 | MAPK8 (0.46) | MAPK8MAPK10GSK3BPRNPPPARG | |
| SCHEMBL12508090 | 0.78 | SLC6A1 (0.43) | MAPK8MAPK10GSK3BPRNPPPARG | |
| SCHEMBL12948208 | 0.78 | PRKCI (0.43) | MAPK8MAPK10ALDH1A1GSK3BPRNP | |
| SCHEMBL5247962 | 0.77 | MAPT (0.47) | MAPK8MAPK10ALDH1A1NPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010101967-A2 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5763437-A | Benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
| EP-0804425-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004254-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4110342-A | PENICILLIN AND CEPHALOSPORIN INTERMEDIATES | PFIZER INC. (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | MAPK8 837/4885MAPK10 552/4885ALDH1A1 1169/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | MAPK8 837/4885MAPK10 552/4885ALDH1A1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.